Jade Bioscience Reports Preclinical Data For JADE301

September 30, 2026 — 08:16 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Jade Biosciences, Inc. (JBIO) announced preclinical data for JADE301, an investigational, anti-IFN-Beta monoclonal antibody being developed for dermatomyositis, a rare autoimmune disease that can cause skin inflammation and muscle weakness.

JADE301 showed selective binding to IFN-Beta and greater functional potency than dazukibart comparator in several human cell models, according to the company. In non-human primate, the drug showed an approximately 25-day half-life after subcutaneous dosing and was well tolerated at the doses tested.

Jade expects to begin a Phase 1 trial in 24 healthy volunteers in the fourth quarter of 2026, with interim data anticipated in the second half of 2027.

JBIO closed Tuesday's trading at $14.18, down 1.18%.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Jade Bioscience Reports Preclinical Data For JADE301

Tags

Latest Articles